Metabolex completes enrollment for Phase II dyslipidemia trial
The randomized, double-blind study is designed to assess the drug’s effect on dyslipidemia and insulin resistance, and will evaluate two different doses of MBX-8025 given over an eight-week
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.